

Volition 

 nu.q
nets

Introducing Nu.Q[®] NETs

Monitoring the immune system to save lives.

We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics.

Our mission is to save lives and improve outcomes for millions of people and animals worldwide.

About Volition


- We are leading experts in epigenetics
- Developed best-in-class technology
- Purpose-built R&D & production facilities in Belgium & USA
- Headquarters in the USA, with offices in Belgium, UK & Singapore

For more information

- Contact us at asknu.qnets@volition.com
- Visit www.volition.com

References:


- S N Stanford et al 'Identifying tools to track hypercoagulability in COVID-19 patients: Exploring global haemostasis (ROTEM) and neutrophil extracellular traps (NETs) immunoassays', ISTH 2021
- C Rea et al 'Circulating Nucleosomes Immunoassay: Evaluating a Clinically Applicable Test to Risk Stratify COVID-19 and Target Anticoagulation', ISTH 2021
- E Cavalier et al 'Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression', Front. Mol. Biosci. 2021 doi: 10.3389/fmolb.2021.600881
- A Aswani et al 'Therapeutic removal of NETs from blood in a pig model of sepsis', E-ISFA 2021
- L Morimont et al 'Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients', ISTH 2022



Volition 

Introducing Nu.Q[®] NETs

We are a multinational epigenetics company and we aim to revolutionize the diagnosis and treatment of life-altering diseases.



Our ground-breaking technology

We are dedicated to advancing the science of epigenetics. Our patented Nucleosomics™ technology isolates any abnormal circulating nucleosomes from the blood for quantification and analysis.

How will Nucleosomics™ make a difference?


Our transformational technology has a wide range of applications, including the detection and monitoring of NETosis, an abnormal immune response that can lead to severe complications in COVID-19 and sepsis patients.

What is NETosis?

NETosis is a unique form of cell death that is characterized by the release of neutrophil extracellular traps ("NETs"), composed of decondensed chromatin, that trap and kill bacteria and viral particles.

Although NETs play an important role in our immune system, excessive production can lead to tissue damage, the formation of microthrombi, and in severe cases, sepsis, shock, and death.

Elevated levels of NETs are associated with poor patient outcomes in a range of diseases, such as COVID-19, but also including sepsis and cancer.



Introducing Nu.Q[®] NETs

Nu.Q[®] NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis. Our assay can be used to identify patients with clinically relevant elevated levels of circulating NETs and enable physicians to rapidly treat these patients.

Nu.Q[®] NETs will support clinical decision-making, enabling physicians to act quickly, improving patient outcomes and patient management.

How can Nu.Q[®] NETs be used?

Nu.Q[®] NETs is registered for use in Europe in both ELISA (Enzyme-Linked Immunosorbent Assay) and automated ChLIA (ChemiLuminescence ImmunoAssay) formats.

- We are currently working with teams at four major hospital across the UK and France, undertaking studies to test our technology as a diagnostic aid for Sepsis and COVID-19, to monitor disease progression and treatment response.
- We are also working with **SanterSus**, which has in development a transformational technology that cleanses blood of NETs as a sepsis treatment. They used Nu.Q[®] NETs within an animal study to measure treatment response and have moved to their first human trial, with results due shortly.

